Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Feb. 28, 2017 | Apr. 10, 2017 | |
Document and Entity Information [Abstract] | ||
Entity Registrant Name | Science to Consumers, Inc. | |
Entity Central Index Key | 1,583,671 | |
Document Type | 10-Q | |
Document Period End Date | Feb. 28, 2017 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --05-31 | |
Entity Well Known Seasoned Issuer | No | |
Entity Voluntary Filers | No | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 31,920,000 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q3 | |
Trading Symbol | beut |
CONDENSED BALANCE SHEETS
CONDENSED BALANCE SHEETS - USD ($) | Feb. 28, 2017 | May 31, 2016 |
Current Assets | ||
Cash and cash equivalents | $ 3,306 | |
Total Current Assets | 3,306 | |
Website development costs | 5,807 | 8,420 |
Total Assets | 5,807 | 11,726 |
Current Liabilities | ||
Accounts payable and accrued liabilities | 27,637 | 16,857 |
Due to related party | 7,656 | 7,675 |
Loan from director | 8,891 | 8,891 |
Loan payable | 31,000 | 31,000 |
Convertible debenture, net of unamortized discount of $7,027 | 10,973 | |
Total Liabilities | 86,157 | 64,423 |
Stockholders' Deficit | ||
Common stock, par value $0.001; 525,000,000 shares authorized, 31,900,000 shares issued and outstanding | 31,900 | 31,900 |
Additional paid in capital | 77,100 | 59,100 |
Stock Subscriptions | 13,150 | 13,150 |
Accumulated deficit | (202,500) | (156,847) |
Total Stockholders' Deficit | (80,350) | (52,697) |
Total Liabilities and Stockholders' Deficit | $ 5,807 | $ 11,726 |
CONDENSED BALANCE SHEETS (Paren
CONDENSED BALANCE SHEETS (Parenthetical) - USD ($) | Feb. 28, 2017 | May 31, 2016 |
Current Liabilities | ||
Unamortized discount | $ 7,027 | $ 0 |
Stockholders' Deficit | ||
Common Stock, Par Value | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 525,000,000 | 525,000,000 |
Common Stock, Shares Issued | 31,900,000 | 31,900,000 |
Common Stock, Shares Outstanding | 31,900,000 | 31,900,000 |
CONDENSED STATEMENTS OF OPERATI
CONDENSED STATEMENTS OF OPERATIONS (unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Feb. 28, 2017 | Feb. 29, 2016 | Feb. 28, 2017 | Feb. 29, 2016 | |
Condensed Statements Of Operations | ||||
REVENUES | ||||
OPERATING EXPENSES | ||||
Amortization expense | 871 | 291 | 2,613 | 581 |
General and administrative | 4,092 | 12,231 | ||
Professional fees | 4,005 | 18,501 | 17,090 | 34,449 |
TOTAL OPERATING EXPENSES | 8,968 | 18,792 | 31,934 | 35,030 |
NET LOSS FROM OPERATIONS | (8,968) | (18,792) | (31,934) | (35,030) |
OTHER EXPENSES | ||||
Accretion of discount on convertible debenture | (9,327) | (10,973) | ||
Interest expense | (899) | (2,746) | ||
NET LOSS FROM OPERATIONS BEFORE TAXES | (19,194) | (18,792) | (45,653) | (35,030) |
Provision for income taxes | ||||
NET LOSS | $ (19,194) | $ (18,792) | $ (45,653) | $ (35,030) |
NET LOSS PER OUTSTANDING SHARE: BASIC AND DILUTED | $ 0 | $ 0 | $ 0 | $ 0 |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED | 31,900,000 | 31,568,000 | 31,900,000 | 30,465,000 |
STATEMENTS OF CASH FLOWS (unaud
STATEMENTS OF CASH FLOWS (unaudited) - USD ($) | 9 Months Ended | |
Feb. 28, 2017 | Feb. 29, 2016 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net loss for the period | $ (45,653) | $ (35,030) |
Adjustments to reconcile net loss: | ||
Accretion of discount on convertible debenture | 10,973 | |
Amortization | 2,613 | 581 |
Changes in assets and liabilities: | ||
Accounts payable and accrued liabilities | 10,780 | 13,852 |
Due to related party | (2,569) | |
CASH FLOWS USED IN OPERATING ACTIVITIES | (23,856) | (20,597) |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Advances from related party | 2,550 | 5,698 |
Proceeds from convertible debenture | 18,000 | |
Proceeds from sale of common stock | 13,150 | |
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES | 20,550 | 18,848 |
NET DECREASE IN CASH AND CASH EQUIVALENTS | (3,306) | (1,749) |
Cash and cash equivalents, beginning of period | 3,306 | 1,749 |
Cash and cash equivalents, end of period | ||
SUPPLEMENTAL CASH FLOW INFORMATION: | ||
Interest paid | ||
Income taxes paid |
ORGANIZATION AND NATURE OF BUSI
ORGANIZATION AND NATURE OF BUSINESS | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 1. ORGANIZATION AND NATURE OF BUSINESS | Science to Consumers, Inc. (the Company) is a development stage company which registered in the State of Nevada on April 15, 2013 formed to distribute Argan Oil products. In addition, the Company is looking to market, sell, and distribute anti-aging products, as on December 29, 2015 the Company signed a five-year exclusive licensing agreement with Biomatrix, Inc. for the Peoples Republic of China and Europe. The agreement will allow Science to Consumers Inc., to market and sell at least six of its special formulated anti-aging products including the DermaLastyl line. The Company will position itself to take full advantage of the distributing its products from their manufacturers to their customers. |
CONDENSED FINANCIAL STATEMENTS
CONDENSED FINANCIAL STATEMENTS | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 2. CONDENSED FINANCIAL STATEMENTS | The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial positions, results of operations, and cash flows on February 28, 2017, and for all periods presented herein, have been made. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Companys May 31, 2016 audited financial statements. The results of operations for the nine months ended February 28, 2017 are not necessarily indicative of the operating results for the full year. |
GOING CONCERN
GOING CONCERN | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 3. GOING CONCERN | The Company has no revenues as of February 28, 2017. The Company currently has accumulated deficit and working capital deficit, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Accordingly, there is substantial doubt about the Companys ability to continue as a going concern. The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that could result from the outcome of this uncertainty. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of managements efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. Accounting Basis The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (GAAP accounting). The Company has adopted a May 31 fiscal year end. Cash and Cash Equivalents The Company considers all highly liquid investments with the original maturities of three months or less to be cash equivalents. The Company had $nil of cash as of February 28, 2017 and $3,306 of cash as of May 31, 2016. Fair Value of Financial Instruments The Companys financial instruments consist of cash and cash equivalents, accounts payable, amounts due to a related party, a loan from a director, a loan payable and a convertible debenture. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Website Development Costs Website development costs consist of costs incurred to develop internet websites to promote, advertise, and earn revenue with respect to the Companys business operations. Costs are amortized on a straight line basis over 3 years from when the internet web site has been completed. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue Recognition The Company recognizes revenue when products are fully delivered or services have been provided and collection is reasonably assured. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options. Basic Income (Loss) Per Share Basic income (loss) per share is calculated by dividing the Companys net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Companys net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of February 28, 2017 and May 31, 2016. Comprehensive Income ASC 220, Comprehensive Income Impact of New Accounting Standards The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position, or cash flow. |
LICENSE AGREEMENT
LICENSE AGREEMENT | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 5. LICENSE AGREEMENT | On December 29, 2015, the Company entered into an exclusive license agreement with Biomatrix Inc. (Biomatrix), a Delaware corporation, pursuant to which the Company obtained the exclusive rights to sell certain proprietary skincare products of Biomatrix by direct to consumer marketing and sales in the territories of China and Europe. In consideration for the marketing, sales and distribution services to be provided by the Company, Biomatrix has agreed to supply product inventory at a rate not less favorable than that provided to any third party. Additionally, Biomatrix has agreed to transfer to the Company 100% equity ownership of Biomatrix Inc. (Biomatrix Arizona), an Arizona corporation, which holds all right and title to the product distribution rights acquired. In consideration of transfer of title and rights acquired, the Company issued 2,000,000 restricted shares of common stock to Biomatrix. Upon closing of the transaction, Biomatrix Arizona will become a wholly owned subsidiary of the Company. As of February 28, 2017, the transaction had not closed and the Company has not received ownership of the Biomatrix Arizona equity. The initial term of the exclusive license agreement is 5 years, subject to the Company achieving minimum sales of $250,000 and $500,000 during the first and second years of the agreement, respectively, commencing after the transaction has closed. Thereafter, the term will automatically renew for successive 5 year periods provided that the Company achieve a minimum $500,000 in sales of the licensed products during each calendar year of the term, excluding the first year. On December 16, 2015, the Company issued to Biomatrix 2,000,000 shares of the Companys common stock pursuant to the license agreement. As of February 28, 2017, the shares of Biomatrix Arizona were not received by the Company and the transaction had not closed. Due to the value of Biomatrix Arizona and the Companys uncertain future revenues generated by the license, the fair value of the 2,000,000 shares issued has been recorded as $nil. |
DUE TO RELATED PARTY
DUE TO RELATED PARTY | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 6. DUE TO RELATED PARTY | As of February 28, 2017, the Company was indebted to the Chief Executive Officer of the Company for $7,656 (May 31, 2016 - $7,675), for expenses paid on behalf of the Company. The amount is unsecured, non-interest bearing and due on demand. |
LOAN FROM DIRECTOR
LOAN FROM DIRECTOR | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 7. LOAN FROM DIRECTOR | As of February 28, 2017, the Company owed a director of the Company $8,891 (May 31, 2016 - $8,891) related to a loan to the Company for business operations. The loan is unsecured, non-interest bearing and due on demand. |
LOAN PAYABLE
LOAN PAYABLE | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 8. LOAN PAYABLE | On May 1, 2016, the Company entered into a loan agreement in which the note holder agreed to provide a loan to the Company in the principal amount of up to $50,000. The loan is unsecured, bears interest at 8.5% per annum and is payable on May 1, 2017. As at February 28, 2017, the note holder has provided $31,000 to the Company pursuant to the loan agreement. As at February 28, 2017, the Company recorded $2,159 of interest payable (May 31, 2016 - $188). |
CONVERTIBLE DEBENTURE
CONVERTIBLE DEBENTURE | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 9. CONVERTIBLE DEBENTURE | On September 26, 2016, the Company issued a convertible debenture for $18,000. Pursuant to the terms of the agreement, the note is unsecured, bears interest at 10% per annum, and is due six months from the date of issuance. At any time up to and including the maturity date, the unpaid amount of principal and interest can be converted at the holders option at a conversion price equal to a 20% discount of the average share closing price for the thirty days preceding the date of conversion, not to be below $0.05 per share. The 20% discount provides for rate of conversion that is below market value, thus is characterized as a beneficial conversion feature. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $18,000 as additional paid-in capital and reduced the carrying value of the convertible debenture to $nil. The carrying value will be accreted over the term of the convertible debenture up to its face value of $18,000. The embedded conversion option does not qualify for derivative accounting and bifurcation under ASC 815 Derivatives and Hedging Convertible Debentures consist of the following as of February 28, 2017: Noteholder (issue date) February 28, 2017 September 26, 2016 debenture $ 18,000 18,000 Less: debt discount (7,027 ) Total $ 10,973 |
COMMON STOCK
COMMON STOCK | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 10. COMMON STOCK | The Company has 525,000,000, $0.001 par value shares of common stock authorized. There were 31,900,000 shares of common stock issued and outstanding as of February 28, 2017. |
WARRANTS
WARRANTS | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 11. WARRANTS | The following table summarizes the continuity of share purchase warrants: Number of Warrants Weighted Average Exercise Price $ Balance, May 31, 2015 150,000 0.50 Issued Balance, May 31, 2016 and February 28, 2017 150,000 0.50 As at February 28, 2017, the following share purchase warrants were outstanding: Number of Warrants Exercise Price $ Expiry Date Weighted Average Remaining Life (years) 50,000 0.50 September 17, 2017 0.55 100,000 0.50 September 18, 2017 0.55 150,000 0.55 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 12. COMMITMENTS AND CONTINGENCIES | The Company neither owns nor leases any real or personal property. An officer has provided office services without charge. There is no obligation for the officer to continue this arrangement. Such costs are immaterial to the financial statements and accordingly are not reflected herein. The officers and directors are involved in other business activities and most likely will become involved in other business activities in the future. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Feb. 28, 2017 | |
Notes to Financial Statements | |
NOTE 13. SUBSEQUENT EVENTS | In accordance with SFAS 165 (ASC 855-10) the Company has analyzed its operations subsequent to February 28, 2017 to the date these financial statements were issued. |
SUMMARY OF SIGNIFCANT ACCOUNTIN
SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Feb. 28, 2017 | |
Summary Of Signifcant Accounting Policies Policies | |
Basis of Presentation | The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. |
Accounting Basis | The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (GAAP accounting). The Company has adopted a May 31 fiscal year end. |
Cash and Cash Equivalents | The Company considers all highly liquid investments with the original maturities of three months or less to be cash equivalents. The Company had $nil of cash as of February 28, 2017 and $3,306 of cash as of May 31, 2016. |
Fair Value of Financial Instruments | The Companys financial instruments consist of cash and cash equivalents, accounts payable, amounts due to a related party, a loan from a director, a loan payable and a convertible debenture. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. |
Website Development Costs | Website development costs consist of costs incurred to develop internet websites to promote, advertise, and earn revenue with respect to the Companys business operations. Costs are amortized on a straight line basis over 3 years from when the internet web site has been completed. |
Income Taxes | Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. |
Use of Estimates | The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Revenue Recognition | The Company recognizes revenue when products are fully delivered or services have been provided and collection is reasonably assured. |
Stock-Based Compensation | Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options. |
Basic Income (Loss) Per Share | Basic income (loss) per share is calculated by dividing the Companys net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Companys net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of February 28, 2017 and May 31, 2016. |
Comprehensive Income | ASC 220, Comprehensive Income |
Impact of New Accounting Standards | The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position, or cash flow. |
CONVERTIBLE DEBENTURE (Tables)
CONVERTIBLE DEBENTURE (Tables) | 9 Months Ended |
Feb. 28, 2017 | |
Convertible Debenture Tables | |
Summary of convetible debenture | Convertible Debentures consist of the following as of February 28, 2017: Noteholder (issue date) February 28, 2017 September 26, 2016 debenture $ 18,000 18,000 Less: debt discount (7,027 ) Total $ 10,973 |
WARRANTS (Tables)
WARRANTS (Tables) | 9 Months Ended |
Feb. 28, 2017 | |
Warrants Tables | |
Schedule of Share Purchase Warrants, Activity | Number of Warrants Weighted Average Exercise Price $ Balance, May 31, 2015 150,000 0.50 Issued Balance, May 31, 2016 and February 28, 2017 150,000 0.50 |
Schedule of Purchase Warrants Outstanding | Number of Warrants Exercise Price $ Expiry Date Weighted Average Remaining Life (years) 50,000 0.50 September 17, 2017 0.55 100,000 0.50 September 18, 2017 0.55 150,000 0.55 |
ORGANIZATION AND NATURE OF BU22
ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) | 9 Months Ended |
Feb. 28, 2017 | |
Organization And Nature Of Business Details Narrative | |
Date of incorporation | Apr. 15, 2013 |
State of incorporation | Nevada |
GOING CONCERN (Details Narrativ
GOING CONCERN (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Feb. 28, 2017 | Feb. 29, 2016 | Feb. 28, 2017 | Feb. 29, 2016 | |
Going Concern Details Narrative | ||||
REVENUES |
SUMMARY OF SIGNIFICANT ACCOUN24
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 9 Months Ended | |||
Feb. 28, 2017 | May 31, 2016 | Feb. 29, 2016 | May 31, 2015 | |
Summary Of Significant Accounting Policies Details Narrative | ||||
Cash and cash equivalents | $ 3,306 | $ 1,749 | ||
Amortized period of internet web site | 3 years |
LICENSE AGREEMENT (Details Narr
LICENSE AGREEMENT (Details Narrative) - Biomatrix Arizona [Member] - USD ($) | 9 Months Ended | ||
Feb. 28, 2017 | Dec. 29, 2015 | Dec. 16, 2015 | |
Percentage of equity ownership | 100.00% | ||
Issuence of restricted common stock | 2,000,000 | 2,000,000 | |
Term of license agreement initially | 5 years | ||
Minimum sales at first year | $ 250,000 | ||
Minimum sales at second year | $ 500,000 | ||
Term of license agreement thereafter | 5 years | ||
Sales revenue thereafter | $ 500,000 |
DUE TO RELATED PARTY (Details N
DUE TO RELATED PARTY (Details Narrative) - USD ($) | Feb. 28, 2017 | May 31, 2016 |
Due to related party | $ 7,656 | $ 7,675 |
Chief Executive Officer [Member] | ||
Due to related party | $ 7,656 | $ 7,675 |
LOAN FROM DIRECTOR (Details Nar
LOAN FROM DIRECTOR (Details Narrative) - USD ($) | Feb. 28, 2017 | May 31, 2016 |
Loan from director | $ 8,891 | $ 8,891 |
Director [Member] | ||
Loan from director | $ 8,891 | $ 8,891 |
LOAN PAYABLE (Details Narrative
LOAN PAYABLE (Details Narrative) - USD ($) | 9 Months Ended | |
Feb. 28, 2017 | May 31, 2016 | |
Loan Payable Details Narrative | ||
Principal amount loan payable | $ 50,000 | |
Interest rate | 8.50% | |
Loan payable | $ 31,000 | $ 31,000 |
Interest payable | $ 2,159 | $ 188 |
CONVERTIBLE DEBENTURE (Details)
CONVERTIBLE DEBENTURE (Details) - USD ($) | Feb. 28, 2017 | Sep. 26, 2016 | May 31, 2016 |
Convertible Debenture Details | |||
September 26, 2016 debenture | $ 18,000 | $ 18,000 | |
Convertible Subordinated Debt | 18,000 | ||
Less: debt discount | (7,027) | $ 0 | |
Total | $ 10,973 |
CONVERTIBLE DEBENTURE (Details
CONVERTIBLE DEBENTURE (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||
Sep. 26, 2016 | Feb. 28, 2017 | Feb. 29, 2016 | Feb. 28, 2017 | Feb. 29, 2016 | |
Convertible Debenture Details Narrative | |||||
Convertible debenture | $ 18,000 | $ 18,000 | $ 18,000 | ||
Interest rate | 10.00% | ||||
Conversion rate | 20.00% | ||||
Closing price | $ 0.05 | ||||
Accretion of discount on convertible debenture | $ 9,327 | 10,973 | |||
Accrued interest | $ 775 | ||||
Additional paid-in capital | $ 18,000 | ||||
Debenture face value | $ 18,000 |
COMMON STOCK (Details Narrative
COMMON STOCK (Details Narrative) - $ / shares | Feb. 28, 2017 | May 31, 2016 |
Common Stock Details Narrative | ||
Common Stock, Par Value | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 525,000,000 | 525,000,000 |
Common Stock, Shares Issued | 31,900,000 | 31,900,000 |
Common Stock, Shares Outstanding | 31,900,000 | 31,900,000 |
WARRANTS (Details)
WARRANTS (Details) | 9 Months Ended |
Feb. 28, 2017$ / sharesshares | |
Warrants Details | |
Number of Warrants, Beginning | shares | 150,000 |
Number of Warrants issued | shares | |
Number of Warrants, Ending | shares | 150,000 |
Weighted Average Exercise Price, Beginning | $ / shares | $ 0.50 |
Weighted Average Exercise Price issued | $ / shares | |
Weighted Average Exercise Price, Ending | $ / shares | $ 0.50 |
WARRANTS (Details 1)
WARRANTS (Details 1) | 9 Months Ended |
Feb. 28, 2017$ / sharesshares | |
Number of Warrants | 150,000 |
Weighted Average Remaining Life (years) | 9 months 18 days |
Warrant [Member] | |
Number of Warrants | 50,000 |
Exercise Price | $ / shares | $ 0.50 |
Expiry Date | September 17, 2017 |
Weighted Average Remaining Life (years) | 9 months 18 days |
Warrant One [Member] | |
Number of Warrants | 100,000 |
Exercise Price | $ / shares | $ 0.50 |
Expiry Date | September 18, 2017 |
Weighted Average Remaining Life (years) | 9 months 18 days |